Cara Therapeutics | CARA - Cash And Equivalent


Cara Therapeutics reported $20.73M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Assertio Holdings USD 38.5M 8.59M Sep/2025
Cara Therapeutics USD 20.73M 684K Dec/2025
Cassava Sciences USD 86.57M 8.93M Mar/2026
Chugai Pharma JPY 426.6B 29.83B Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
RedHill Biopharma USD 2.87M 1.75M Jun/2025
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025